Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVLITE vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Emergency contraception,Contraception (as part of combination oral contraceptives or intrauterine system),Off-label: menstrual disorders, endometriosis
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP3A4; reduced to inactive metabolites; excreted in urine and feces.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Levonorgestrel: ~99% bound to sex hormone-binding globulin (SHBG) and albumin; Ethinyl estradiol: ~98% bound to albumin
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Levonorgestrel: 1.8 L/kg; Ethinyl estradiol: 2.5 L/kg; clinical meaning: extensive tissue distribution
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: ~100% for both levonorgestrel and ethinyl estradiol (high bioavailability due to minimal first-pass metabolism)
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic disease (Child-Pugh Class C). For mild to moderate impairment (Child-Pugh A/B), use with caution and monitor liver function.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenarchal pediatric patients; safety and efficacy not established in prepubertal children.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women; no specific geriatric dosing studies available.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events. Women over 35 who smoke should not use combination hormonal contraceptives.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders,Hepatic disease,Hypertension,Diabetes,Gallbladder disease,Depression,Ectopic pregnancy risk (emergency contraception),Reduced efficacy with CYP3A4 inducers
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Severe hepatic disease,Known or suspected breast cancer,History of thromboembolic disorders,Hypersensitivity to levonorgestrel
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No known significant food interactions. Grapefruit and grapefruit juice do not interact with ethinyl estradiol or levonorgestrel. However, a high-fat meal may increase absorption of some oral contraceptives; consistency in taking with or without food is recommended.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. Ethinyl estradiol and levonorgestrel are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defects from first-trimester exposure. Second and third trimester exposure may be associated with genitourinary abnormalities and masculinization of female fetuses.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk in small amounts. Ethinyl estradiol concentration in milk ~0.02-0.1 ng/m L; levonorgestrel M/P ratio ~0.35-1.0. No adverse effects reported at typical doses. May reduce milk production; use caution in lactating women, especially with high doses.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment applicable as use is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, decreased binding protein) are irrelevant due to contraindication.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
LEVLITE is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Use with caution in women with migraines with aura due to increased stroke risk. Smoking increases cardiovascular risk, especially in women over 35. Monitor blood pressure at baseline and periodically. Consider alternative contraception in women with uncontrolled hypertension or history of venous thromboembolism.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time each day.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Do not smoke while taking this medication, as it increases the risk of blood clots and heart problems.,Use barrier contraception if you also take certain antibiotics or anticonvulsants.,Common side effects include nausea, headache, and breast tenderness, which often improve after a few months.,Seek immediate medical help for symptoms of a blood clot: leg pain/swelling, sudden chest pain, or trouble breathing.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVLITE vs ALYACEN 777, answered by our medical review team.
LEVLITE is a Oral Contraceptive that works by Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVLITE and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVLITE is: One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVLITE and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVLITE is classified as Category C. FDA Pregnancy Category X. Ethinyl estradiol and levonorgestrel are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defec. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.